Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) Director Rebecca Taub sold 647 shares of the company's stock in a transaction on Monday, January 26th. The shares were sold at an average price of $492.42, for a total value of $318,595.74. Following the completion of the transaction, the director directly owned 452,704 shares in the company, valued at approximately $222,920,503.68. This trade represents a 0.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Rebecca Taub also recently made the following trade(s):
- On Tuesday, January 20th, Rebecca Taub sold 2,238 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $490.77, for a total value of $1,098,343.26.
- On Friday, January 9th, Rebecca Taub sold 18,410 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $522.40, for a total transaction of $9,617,384.00.
- On Friday, January 9th, Rebecca Taub sold 240 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $550.33, for a total transaction of $132,079.20.
- On Wednesday, December 10th, Rebecca Taub sold 18,650 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $552.15, for a total transaction of $10,297,597.50.
Madrigal Pharmaceuticals Stock Performance
NASDAQ:MDGL opened at $499.17 on Tuesday. The stock has a market capitalization of $11.34 billion, a P/E ratio of -38.37, a PEG ratio of 4.66 and a beta of -1.00. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.26 and a current ratio of 3.44. Madrigal Pharmaceuticals, Inc. has a fifty-two week low of $265.00 and a fifty-two week high of $615.00. The company has a 50 day moving average price of $558.07 and a 200 day moving average price of $461.64.
Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) EPS for the quarter, missing analysts' consensus estimates of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative return on equity of 41.50% and a negative net margin of 39.04%. Equities research analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current year.
Institutional Investors Weigh In On Madrigal Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of MDGL. Flagship Harbor Advisors LLC purchased a new stake in shares of Madrigal Pharmaceuticals during the 4th quarter worth $29,000. Aventura Private Wealth LLC acquired a new stake in Madrigal Pharmaceuticals in the fourth quarter valued at $36,000. Mather Group LLC. purchased a new stake in Madrigal Pharmaceuticals during the 3rd quarter worth about $33,000. Global Retirement Partners LLC boosted its position in shares of Madrigal Pharmaceuticals by 221.7% during the 3rd quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 51 shares in the last quarter. Finally, First Horizon Corp purchased a new position in shares of Madrigal Pharmaceuticals in the 3rd quarter valued at about $34,000. 98.50% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several analysts have recently issued reports on MDGL shares. Piper Sandler increased their price target on shares of Madrigal Pharmaceuticals from $540.00 to $900.00 and gave the stock an "overweight" rating in a research report on Friday, December 19th. Citizens Jmp increased their target price on shares of Madrigal Pharmaceuticals from $527.00 to $745.00 and gave the stock a "market outperform" rating in a report on Tuesday, January 20th. Cantor Fitzgerald upgraded shares of Madrigal Pharmaceuticals from a "neutral" rating to an "overweight" rating in a research note on Tuesday, November 4th. Bank of America raised Madrigal Pharmaceuticals from an "underperform" rating to a "neutral" rating and upped their price objective for the stock from $266.00 to $445.00 in a research report on Monday, November 3rd. Finally, B. Riley lifted their target price on Madrigal Pharmaceuticals from $560.00 to $670.00 and gave the company a "buy" rating in a report on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $632.64.
View Our Latest Analysis on MDGL
Madrigal Pharmaceuticals Company Profile
(
Get Free Report)
Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company's pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.
The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
